» Articles » PMID: 17911628

CD8 T Cells Inhibit Respiratory Syncytial Virus (RSV) Vaccine-enhanced Disease

Overview
Journal J Immunol
Date 2007 Oct 4
PMID 17911628
Citations 73
Authors
Affiliations
Soon will be listed here.
Abstract

Vaccination of children with a formalin-inactivated (FI) respiratory syncytial virus (RSV) vaccine led to exacerbated disease including pulmonary eosinophilia following a natural RSV infection. Immunization of BALB/c mice with FI-RSV or a recombinant vaccinia virus (vv) expressing the RSV attachment (G) protein (vvG) results in a pulmonary Th2 response and eosinophilia after RSV challenge that closely mimics the RSV vaccine-enhanced disease observed in humans. The underlying causes of RSV vaccine-enhanced disease remain poorly understood. We demonstrate here that RSV M2-specific CD8 T cells reduce the Th2-mediated pathology induced by vvG-immunization and RSV challenge in an IFN-gamma-independent manner. We also demonstrate that FI-RSV immunization does not induce a measurable RSV-specific CD8 T cell response and that priming FI-RSV-immunized mice for a potent memory RSV-specific CD8 T cell response abrogates pulmonary eosinophilia after subsequent RSV challenge. Our results suggest that the failure of the FI-RSV vaccine to induce a CD8 T cell response may have contributed to the development of pulmonary eosinophilia and augmented disease that occurred in vaccinated individuals.

Citing Articles

Evaluation of adenoviral vector Ad19a encoding RSV-F as novel vaccine against respiratory syncytial virus.

Fuchs J, Hubner J, Schmidt A, Irrgang P, Maier C, Vieira Antao A NPJ Vaccines. 2024; 9(1):205.

PMID: 39472590 PMC: 11522487. DOI: 10.1038/s41541-024-01001-z.


Inhibiting retinoic acid signaling in dendritic cells suppresses respiratory syncytial virus infection through enhanced antiviral immunity.

Farazuddin M, Acker G, Zourob J, OKonek J, Wong P, Morris S iScience. 2024; 27(7):110103.

PMID: 39045100 PMC: 11263793. DOI: 10.1016/j.isci.2024.110103.


Dissolving Microneedles Loaded with Nanoparticle Formulation of Respiratory Syncytial Virus Fusion Protein Virus-like Particles (F-VLPs) Elicits Cellular and Humoral Immune Responses.

Menon I, Patil S, Bagwe P, Vijayanand S, Kale A, Gomes K Vaccines (Basel). 2023; 11(4).

PMID: 37112778 PMC: 10144232. DOI: 10.3390/vaccines11040866.


Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12-23 Months of Age.

Diez-Domingo J, Saez-Llorens X, Rodriguez-Weber M, Epalza C, Chatterjee A, Chiu C J Infect Dis. 2022; 227(11):1293-1302.

PMID: 36484484 PMC: 10226655. DOI: 10.1093/infdis/jiac481.


Prior respiratory syncytial virus infection reduces vaccine-mediated Th2-skewed immunity, but retains enhanced RSV F-specific CD8 T cell responses elicited by a Th1-skewing vaccine formulation.

Eichinger K, Kosanovich J, Perkins T, Oury T, Petrovsky N, Marshall C Front Immunol. 2022; 13:1025341.

PMID: 36268035 PMC: 9577258. DOI: 10.3389/fimmu.2022.1025341.